Dechra launches Tri-Solfen®, a new topical anaesthetic and antiseptic gel
23 February 2023
Dechra has added to its extensive anaesthesia and analgesia portfolio with the launch of the innovative new anaesthetic and antiseptic gel, Tri-Solfen.
Dechra has added to its extensive anaesthesia and analgesia portfolio with the launch of the innovative new anaesthetic and antiseptic gel, Tri-Solfen.
Licensed in the UK for local anaesthesia during and following castration of piglets and provision of castration wound antisepsis, Tri-Solfen contains four active ingredients in a single product to deliver multiple benefits. These include lidocaine and bupivacaine to deliver rapid onset and prolonged local anaesthesia effect, while adrenalin reduces blood loss and cetrimide lowers the risk of infection.
The gel is easy-to-administer and fast-acting (effective in just 30 seconds), providing a practical tool to improve animal welfare via cutaneous and epilesional use.
Tri-Solfen was originally developed and launched in Australia by Medical Ethics, a company that specialises in pain management treatments for humans and animals. More than 100 million animals have been successfully treated with Tri-Solfen in Australia, New Zealand and Portugal, where it is licensed for disbudding, dehorning, castration and general wound treatments in cattle, sheep, pigs and horses.
“Tri-Solfen is widely used around the world for a variety of treatments,” comments Alana McGlade MRCVS, national sales manager at Dechra. “The introduction of Tri-Solfen to our extensive anaesthesia and analgesia range provides vets with exciting new options for local anaesthesia and animal welfare and it is a welcome addition to our product portfolio.”
For further information on Tri-Solfen please contact your local Dechra territory sales manager or visit www.dechra.co.uk.
For press information, please contact:
Jessica Henman, Vita Communications
Email: jessica.henman@vitacomms.com
Tel: 01488 683862 or 07771 897954
NOTES TO EDITORS
Tri-Solfen contains lidocaine, bupivacaine, adrenalin and cetrimide. Legal category: POM-V. Please refer to the product packaging and leaflets for information about side effects, precautions, warnings and contra-indications.
Dechra Veterinary Products Ltd is part of Dechra Pharmaceuticals PLC (‘Dechra’) and offers a range of pharmaceutical products and instruments to veterinary practices in the UK and Republic of Ireland. Dechra Veterinary Products specialises in the development and marketing of licensed branded pharmaceuticals in the global veterinary market.
An innovative company, it invests in the development of products and services while providing a high level of support to vets. Dechra's expertise spans dermatology, endocrinology, equine medicine, ophthalmology, critical care and diet and nutrition. Major brands include: Vetoryl® Capsules, for the treatment of canine hyperadrenocorticism (Cushing's syndrome); Dermatology brands Canaural®, Isaderm® Gel and Malaseb® Shampoo; Felimazole® Tablets, for treating feline hyperthyroidism; Equipalazone®, the anti-inflammatory and analgesic for equine musculoskeletal disorders and ophthalmic product Isathal®.